What Is Step Therapy for GLP-1 Medications?

Step therapy, prior authorization, and denial are three different things

They are separate steps in a sequence.

1. Prior authorization is the review. Preauthorization is sometimes called prior authorization, prior approval, or precertification. A health insurance plan may require preauthorization for certain services before the patient receives them, except in an emergency. Plans and issuers have 15 calendar days to make a pre-service (prior authorization) benefit determination.

2. Step therapy is a condition inside that review. It is one of the criteria the plan applies when deciding the request.

3. Denial is one possible outcome of the review. A notice of adverse benefit determination must state the specific reasons for the determination, including the denial code and its corresponding meaning. If step therapy is the reason, that notice is where it will be named.

And preauthorization is not a promise that the health insurance plan will cover the cost of the service or drug.

If you are still working out whether your plan covers GLP-1s at all, start there instead: does insurance cover GLP-1 weight loss medication.

Before you get denied: what to check and what to ask

Get your plan's actual criteria in hand before a request is submitted.

Start with your plan's drug list — the formulary, the document that tells you what the plan will consider at all. Then call the member services number on your insurance card and ask, in this order:

• Is the specific drug and dosage form my prescriber wrote on the formulary?
• Does it require prior authorization?
• Are there step therapy or "try first" requirements attached to it? Which drugs, and for how long?
• What counts as documented failure of those drugs?
• Can you send me the plan's written coverage criteria for this drug?

Write down the day, time, name, and title of the person you speak to. If you are later denied, a notice of adverse benefit determination must describe the internal guidelines or criterion used in making the determination and inform the consumer that a copy of the internal requirements will be provided free of charge upon request, so the criteria are obtainable either way.

Be precise about the drug and its form, because the products are not equivalent on paper. Wegovy is marketed in two distinct dosage forms under a single brand name and a single FDA label: WEGOVY (semaglutide) injection, solution, and WEGOVY (semaglutide) tablet. Zepbound is administered exclusively as a subcutaneous injection; the FDA label describes it only as 'injection, for subcutaneous use' and no oral dosage form of Zepbound is listed in the label. And the labeled purpose differs across brands: the Mounjaro FDA-approved indication is limited to glycemic control in type 2 diabetes mellitus; chronic weight management is not an approved indication under the Mounjaro label.

For weight-related requests, the labeled indications are the anchor. Zepbound (tirzepatide) is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. Wegovy injection is indicated, in combination with a reduced calorie diet and increased physical activity, to reduce excess body weight in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.

A step requirement is a separate gate from any BMI threshold, and a telehealth program's own enrollment rules are separate from both. A program eligibility rule is not a coverage rule, and neither one determines whether a medication is clinically appropriate for you.

For patients with commercial insurance, Measured performs a benefits check to determine which medications may be covered under the patient's plan. Measured's insurance concierge team submits prior authorizations on the patient's behalf and keeps the patient updated on the insurance plan's determination.

Step therapy exceptions: filed before an appeal, not after

An exception request is a coverage request, not an appeal of a denial; it can come first.

An enrollee has the right to follow their insurance company's drug exceptions process, which allows them to get a prescribed drug that is not normally covered by their health plan. To get a drug covered through the exceptions process the enrollee's doctor must confirm to the health plan, orally or in writing, that the drug is appropriate for the enrollee's medical condition.

Three recognized grounds support a drug exception request:

• All other drugs covered by the plan have not been or will not be as effective as the drug being requested.
• Any alternative drug covered by the plan has caused or is likely to cause side effects that may be harmful to the enrollee.
• Where the plan limits the number of doses allowed, the allowed dosage has not worked for the enrollee's condition.

While an enrollee is in the drug exceptions process, the plan may give them access to the requested drug until a decision is made. If a drug exception is granted, the health plan generally treats the drug as covered and charges the copayment that applies to the most expensive drugs already covered on the plan. Any amount an enrollee pays for a drug obtained through the exceptions process generally counts toward their deductible and maximum out-of-pocket limits.

If the exception is refused, you are into appeal territory: if a health insurance company will not pay for an enrollee's prescription, the enrollee has the right to appeal the decision and have it reviewed by an independent third party. An enrollee must file an internal appeal within 180 days (6 months) of receiving notice that the claim was denied, and an internal appeal must be completed within 30 days if the appeal concerns a service the enrollee has not yet received. The mechanics are covered in how to appeal a GLP-1 insurance denial.

If internal appeals are exhausted, the terminal path is external review. An enrollee must file a written request for an external review within four months after the date they receive a notice or final determination from the insurer that the claim has been denied, and standard external reviews are decided as soon as possible and no later than 45 days after the request was received. See what is an external review and when should I request one.

One Medicare note: since the inception of the Medicare Part D program, CMS has interpreted the statutory exclusion of 'agents when used for weight loss' to mean anti-obesity medications are coverable under Part D only when used for a medically accepted indication other than weight loss or weight management.

If the ladder will take months: the cash-pay math

Disclosure first: Measured sells a cash-pay subscription; Measured membership fees are not covered by insurance and are paid separately. We have a financial interest in you paying cash.

The coverage side: Measured states that if prior authorization is approved, the patient pays only their plan's copay when picking up the medication from the pharmacy. Measured states that while many patients have GLP-1 copays around $20, actual out-of-pocket cost depends on the patient's specific insurance plan and pharmacy benefits (Measured Help Center, as of August 5, 2026). As of August 5, 2026, Measured prices its program at $99/month for patients with GLP-1 insurance coverage, noting those patients may also have a medication copay. If your plan approves, that is almost always the cheaper path.

The cash side: as of August 5, 2026, Measured's cash pay programs start at $119/month with medication and membership included. As of August 5, 2026, Measured lists Compounded Semaglutide from $119/mo and Compounded Tirzepatide from $219/mo, both "No insurance required" with medication included in the membership price. Measured states that compounded medications are not reviewed or approved by the FDA for safety or effectiveness, and that providers may prescribe them in certain cases to address patient-specific needs or when commercially available medications are not appropriate or available.

Manufacturer self-pay pricing is a third option. Self-pay pricing for the Wegovy pill is advertised at $149 per month for the 1.5 mg and 4 mg doses, with the 4 mg price scheduled to rise to $199 per month after August 31, 2026 (Novo Nordisk, as of August 7, 2026). Self-pay pricing for the Wegovy pen is advertised as a limited-time introductory offer of $199 per month for the first 2 months at the 0.25 mg or 0.5 mg doses, then $349 per month; the Wegovy HD 7.2 mg pen is $399 per month (Novo Nordisk, as of August 4, 2026).

Logistics differ by path: GLP-1s covered by insurance are sent to the patient's pharmacy of choice, while cash-pay GLP-1s, compounded GLP-1s, and oral medications are shipped directly to the patient's home free of charge.

Across both paths, Measured prescribes FDA-approved GLP-1 medications and compounded alternatives, specifically semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), compounded alternatives when brand medications are unavailable, and oral medications including metformin, topiramate, and bupropion/naltrexone. If you want the intake path, see how do I get a GLP-1 prescription online.

Nothing here is a promise of approval, coverage, or savings.

How this page is dated

Last reviewed: August 5, 2026. Prices, plan criteria, and drug lists change; every dollar figure above carries the date it was checked. Confirm current numbers with your plan and the cited source.